Drug Interaction Study Between AZD3480 and Warfarin

AstraZeneca26 enrolled

Overview

The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Alzheimer's Disease

Interventions

AZD3480DRUG

AZD3480 capsules qd, 12 days

PlaceboDRUG

Placebo capsules qd, 12 days

WarfarinDRUG

Warfarin: single dose on day 6

Eligibility

Sex: MALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of signed written informed consent * Clinically normal physical findings and laboratory values Exclusion Criteria: * Clinically significant illness or clinically relevant trauma within three weeks before the first dose * History of clinically significant disease * Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product

Locations (1)

Research SIte

Uppsala, Sweden

Outcomes

Primary Outcomes

PK variables

Time frame: Frequent sampling occasions during days 5 and 6

Secondary Outcomes

Safety variables (adverse events, blood pressure, pulse, safety lab)

Time frame: During the whole treatment period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.